The spectrum of tumors that arise owing to the overexpression of c-Myc and loss of BLM is very similar. Hence, it was hypothesized that the presence of BLM negatively regulates c-Myc functions. By using multiple isogenic cell lines, we observed that the decrease of endogenous c-Myc levels that occurs in the presence of BLM is reversed when the cells are treated with proteasome inhibitors, indicating that BLM enhances c-Myc turnover. Whereas the N-terminal region of BLM interacts with c-Myc, the rest of the helicase interacts with the c-Myc E3 ligase Fbw7. The two BLM domains act as 'clamp and/or adaptor', enhancing the binding of c-Myc to Fbw7. BLM promotes Fbw7-dependent K48-linked c-Myc ubiquitylation and its subsequent degradation in a helicase-independent manner. A subset of BLM-regulated genes that are also targets of c-Myc were determined and validated at both RNA and protein levels. To obtain an in vivo validation of the effect of BLM on c-Myc-mediated tumor initiation, isogenic cells from colon cancer cells that either do or do not express BLM had been manipulated to block c-Myc expression in a controlled manner. By using these cell lines, the metastatic potential and rate of initiation of tumors in nude mice were determined. The presence of BLM decreases c-Myc-mediated invasiveness and delays tumor initiation in a mouse xenograft model. Consequently, in tumors that express BLM but not c-Myc, we observed a decreased ratio of proliferation to apoptosis together with a suppressed expression of the angiogenesis marker CD31. Hence, partly owing to its regulation of c-Myc stability, BLM acts as a 'caretaker tumor suppressor'.
Introduction
Bloom syndrome (BS) is caused by mutation in the RecQ helicase family member, the helicase Bloom syndrome protein (BLM). The disorder is characterized by a predisposition to a wide spectrum of cancers (German, 1997) . BS patients exhibit defects in DNA replication and homologous recombination events, manifested by an increased frequency of sister chromatid exchanges (SCEs) (Chaganti et al., 1974) . BLM regulates homologous recombination by a number of mechanisms, such as disruption of RAD51 nucleofilaments (Bugreev et al., 2007; Tripathi et al., 2007) , prevention of chromosome breakage (Russell et al., 2011) , recruitment of p53 to carry out its own functions during homologous recombination (Sengupta et al., 2003) and enhancement of the interactions between 53BP1 and RAD51 (Tripathi et al., 2008; Tripathi et al., 2007) . BLM is involved in the recognition of the DNA damage by a K63-linked ubiquitindependent mechanism (Tikoo et al., 2013) , transmission of the damage signal to the repair proteins and in repair of the DNA damage during the effector phase (Tikoo and Sengupta, 2010) . Hence, it can be argued that the proposed 'caretaker tumor suppressor' function of BLM (Hickson, 2003) is a culmination of the multiple roles of the helicase.
The proto-oncogene MYC encodes a DNA-binding factor (c-Myc) that can both activate and repress transcription (Dang et al., 2006) . At the post-translational level c-Myc expression is controlled through sequential and reversible phosphorylation at two highly conserved residues, threonine 58 (Thr58) and serine 62 (Ser62) (Dai et al., 2006; Hann, 2006) . This doubly phosphorylated c-Myc binds to its primary E3 ligase complex, which consists of SKP1, CUL1 and F-box proteins (hereafter referred to as SCF Fbw7 ) both in vitro and in vivo (Welcker et al., 2004a; Welcker et al., 2004b; Yada et al., 2004) . Alternatively, dephosphorylated Ser62 and phosphorylated Thr58 in c-Myc can also serve as a dock to recruit the SCF Fbw7 complex, leading to c-Myc ubiquitylation and proteasomal degradation (Yeh et al., 2004) . Transcription of human FBXW7 (hereafter referred to as FBW7) can yield three different transcripts (FBW7a, FBWb and FBWc) that are produced by alternative splicing . The level of c-Myc is regulated by the nucleolar Fbw7c and nucleoplasmic Fbw7a (Grim et al., 2008; Welcker et al., 2004a) .
It is known that cells from BS patients have high levels of c-Myc protein (Sullivan et al., 1989; West et al., 1995) . The spectrum of tumors associated with the overexpression of c-Myc (Nesbit et al., 1999) and the loss of BLM (as in BS patients and BLM-knockout mice) (Hickson, 2003) are also strikingly similar. Hence, we wanted to test the hypothesis that BLM negatively regulates c-Myc functions.
Our results indicate that BLM, indeed, promotes the Fbw7-dependent ubiquitylation and degradation of c-Myc, subsequently causing a delay in c-Myc-dependent initiation of tumors.
Results

BLM regulates c-Myc stability via Fbw7
To determine whether BLM affects endogenous levels of SCF Fbw7 substrates, we compared the levels of five such substrates (c-Myc, cyclin E, c-Jun, B-MyB and KLF5) in three isogenic pairs of cell lines that either do or do not express BLM. Endogenous levels of c-Myc, cyclin E and c-Jun were higher in BS, GM08505+GFP and HCT116 BLM 2/2 cells when compared with A-15 cells (Fig. 1A) , GM08505 + GFP-BLM ( Fig. 1B) and wild-type HCT116 cells (Fig. 1C) , respectively. However, we did not detect any change in the levels of B-MyB and KLF5 in cells that express and do not express BLM (our unpublished data), indicating that the effect of BLM occurs only on a subset of SCF Fbw7 substrates. The increase in the levels of SCF Fbw7 substrates was also not observed in cells obtained from patients suffering from Werner syndrome or Rothmund-Thomson Syndrome, disorders that are caused by gene mutations of two other members of the RecQ helicase family, WRN and RECQL4, respectively (supplementary material Fig. S1A,B) .
To determine whether the role of BLM on the levels of SCF Fbw7 substrates was at the transcriptional level, northern hybridization, reverse transcriptase (RT)-PCR and real-time PCR analysis were carried out (supplementary material Fig. S1C -E).
All the above techniques indicated that the RNA levels of Myc were not substantially altered in presence or absence of BLM. Furthermore, similar levels of c-Myc, cyclin E and c-Jun in BS and A-15 cells were observed after treatment with proteasomal inhibitors, MG132 (Fig. 1D ,E) or LLnL (supplementary material Fig. S1F ). The rate of turnover of endogenous c-Myc was also found to be higher in cells that express BLM, which was determined by treating the cells with protein synthesis inhibitor cycloheximide (Fig. 1F ) or by pulse labeling the cells (supplementary material Fig. S1G ). The half-life of c-Myc in REF52 cells grown in presence of serum is ,90 minutes (Sears et al., 1999) . We found that the half-life of c-Myc increased from 96 minutes in A-15 cells to 310 minutes in BS cells (Fig. 1F, right) .
To determine whether the BLM and the three SCF Fbw7 substrates c-Myc, cyclin E and c-Jun physically interact, GST pull-down assays were carried out with wild-type BLM (1-1417) (supplementary material Fig. S2A,B ), using cyclin E, c-Jun or c-Myc. In vitro interaction assays indicated that BLM interacted Whole-cell extracts were prepared from BS and A-15 cells that were either not treated with cycloheximide (CHX) (0 hours) or treated with CHX for the indicated periods (bottom, left). The nuclear extracts were immunoprecipitated with antibody against c-Myc (13-2500), probed with antibody against c-Myc (#9402). IgG (heavy chain) acts as a control for the amount of the antibody used during immunoprecipitation (top, left) . Quantification of c-Myc levels at different intervals after cycloheximide exposure (right). The graph shows the percentage of c-Myc levels (mean 6 s.d.) of three experiments. with all three tested SCF Fbw7 substrates ( Fig. 2A,B) . Specifically the N-terminal region of BLM interacted with the C-terminal region of c-Jun, which contains the DNA-binding domain and leucine zipper module ( Fig. 2A , middle and bottom blot, and supplementary material Fig. S2C ). The N-terminal region of BLM also interacted with c-Myc (Fig. 2B, right) . The c-Myc-BLM interaction was not diminished when c-Myc was mutated at Thr58 and Ser62 (Fig. 2C ). On the basis of the interaction studies with the C-terminal fragments, it was deduced that amino acids 300-410 of c-Myc -which encompass the basic region and the helix loop helix (HLH) -minimally interacts with BLM ( Fig. 2D ,E; supplementary material Fig. S2D ,E). However, due to the inherent flaws that can happen due to fragment-based analysis, two new c-Myc fragments were generated, namely c-Myc (300-410) and Myc (D300-410) (supplementary material Fig.  S2D ,E). We hoped that Myc (D300-410), which was generated on the entire c-Myc, would not interact with BLM and, indeed, found that Myc (300-410) but not Myc (D300-410), interacts with BLM ( Fig. 2F ). Reciprocal immunoprecipitations by using either antibodies against c-Myc or BLM ( Fig. 2G ) indicated that, in vivo, the two endogenous proteins constitutively interact. Both BLM and c-Myc have been separately reported to localize to the nucleoli (Arabi et al., 2005; Yankiwski et al., 2000) , the subnuclear compartment implicated for c-Myc degradation (Arabi et al., 2005; Welcker et al., 2004a) . Immunofluorescence staining with ice-cold methanol:acetone fixation indicated that overexpressed Myc and BLM were present in both nucleoplasm and nucleolus (identified by DAPI exclusion). BLM and c-Myc colocalized extensively in the nucleolus and, to a limited extent, in the nucleoplasm (Fig. 2H ). Endogenous c-Myc and BLM in A-15 cells also colocalized in both nucleolus and nucleoplasm ( Fig. 2I ). However, Myc-BLM colocalization was not observed in the PML nuclear bodies, where BLM was also found. Compared with A-15 cells, the endogenous c-Myc in BS cells was substantially more cytoplasmic ( Fig. 2I ). This might indicate a role of BLM in the transport of c-Myc from the cytoplasm to the nucleus.
The ubiquitylation and subsequent degradation of c-Myc in cells can occur either by phosphorylation-dependent or independent mechanisms that are mediated by two different E3 ligases of c-Myc, namely Fbw7 and Skp2 (Kim et al., 2003; Yada et al., 2004) . Additionally, a conserved phosphodegron in c-Myc consisting of a central phosphothreonine residue followed by a cysteine and an additional priming phosphodegron by GSK3b in the +4 position is required . So the effect of BLM on c-Myc ubiquitylation and degradation could be a reflection of the activity of GSK3b or the levels of the two E3 ligases that are known to be involved in c-Myc degradation. Using two independent assay techniques, we found that the extent of phosphorylation of GSK3b serine 9 (a marker for the intracellular active GSK3b) is similar in cells expressing and not expressing BLM (Fig. 3A ). This indicated that differential GSK3b signaling did not depend on the absence or presence of the helicase. By using a validated antibody against Fbw7 (Fig. 3B ), the endogenous levels of Fbw7 and Skp2 were found to be similar in A-15 and BS cells ( Fig. 3C ). Interestingly, BLM interacted specifically with Fbw7 but not Skp2 (Fig. 3D ).
BLM enhanced the binding of Fbw7 with c-Myc
Since BLM affected c-Myc stability ( Fig. 1 ) and also interacted with c-Myc (Fig. 2) , we hypothesized that BLM directly modulates the interaction of c-Myc with its E3 ligase Fbw7. In vitro interaction assays carried out with all the three isoforms of Fbw7 (supplementary material Fig. S3A ) indicated that the E3 ligase interacts with GST-tagged BLM (1-1417) but not to GST alone ( Fig. 4A ). Ability of BLM to interact with Fbw7 (DN) ( Fig. 4A) indicates that BLM-Fbw7 interaction occurs through the common C-terminal dimerization, F box and WD40 domains of the Fbw7 isoforms. Since BLM is a nuclear protein, we were interested in the interaction between BLM-Fbw7a and BLM-Fbw7c. Hence, to determine the subnuclear location where BLM could interact with Fbw7, we carried out immunofluorescence staining following the overexpression of the tagged version of the two proteins (because endogenous Fbw7 could not be detected by any available antibody against Fbw7 in immunofluorescence experiments). As known in literature (Yankiwski et al., 2000) BLM was observed in both nucleus and nucleoplasm. In these two subnuclear compartments BLM colocalized with either Fbw7a in the nucleoplasm or with Fbw7c in the nucleolus (Fig. 4B) .
The above results led to the hypothesis that BLM simultaneously binds to both c-Myc and Fbw7. We found that, except the N-terminal (1-212) amino acids, the rest of BLM interacts with both Fbw7a and Fbw7c (Fig. 4C ). The interaction of BLM with Fbw7 was also observed using a BLM recombinant protein that lacked the first 212 amino acids (our unpublished observations), thereby verifying the authenticity of the interaction. Since two distinct regions of BLM interacted with c-Myc and Fbw7, we hypothesized that maybe BLM acts as a 'clamp/adaptor' protein, thereby enhancing c-Myc interaction with Fbw7. To test this hypothesis, assays were carried for which we used bacterially expressed differently tagged recombinant proteins (Fig. 4D ) or a combination of recombinant and in vitro translated proteins (supplementary material Fig. S3B ). In both the assays, the addition of wild-type BLM (1-1417) enhanced the Fig. S3B ) were authentic and not due to the presence of additional cellular proteins that may have been present in the rabbit reticulocyte system. In vivo, endogenous BLM interacted with both Fbw7a and Fbw7c (Fig. 4E ). Furthermore, we observed increased levels of endogenous Fbw7 isoforms that were able to form complexes with endogenous c-Myc in A-15 cells; this was despite the presence of more endogenous c-Myc in BS cells (Fig. 4F ). Altogether these results indicate that BLM enhanced the binding of c-Myc to Fbw7.
Phosphorylation of c-Myc at Thr58/Ser62 is an important parameter for its ubiquitylation-dependent degradation (Welcker et al., 2004a; Welcker et al., 2004b; Yada et al., 2004) by Fbw7. Hence, we wanted to determine whether the level of c-Myc phosphorylated at Thr58 and Ser62 was altered in absence of BLM. Using a validated antibody against phosphorylated c-Myc (Thr58/Ser62) (supplementary material Fig. S3C ), more Thr58/ Ser62 biphosphorylated c-Myc forms were observed in A-15 cells (supplementary material Fig. S3D ), even though the levels of total c-Myc was found to be higher in BS cells. However, the presence of either GSK3b inhibitor or l phosphatase did not abolish the effect of BLM on the interaction between c-Myc and Fbw7 (supplementary material Fig. S3B , middle panel). Moreover, wild-type BLM enhanced the physical interaction of Fbw7 with wild-type and mutant (T58A, S62A) c-Myc to equal extent (supplementary material Fig. S3E ). Together, these results (supplementary material Fig. S3B , middle panel and S3E) indicate that BLM-mediated enhancement of Fbw7-Myc interaction does not depend on the phosphorylation of c-Myc residues Ser58 and Thr62.
BLM enhanced Fbw7-mediated K48-linked c-Myc ubiquitylation
On the basis of the above results, we wanted to test whether BLM has a stimulatory effect on Fbw7-dependent c-Myc ubiquitylation. First, we verified that the Fbw7 that we used can act as an E3 ligase for c-Myc over a variety of concentrations (supplementary material Fig. S4A ). The authenticity of the c-Myc ubiquitylation by Fbw7 was also verified by using a F-box deletion (Fbw7cDF) mutant. As expected, the Fbw7cDF mutant showed loss of c-Myc ubiquitylation (supplementary material Fig. S4B ).
Next, we wanted to determine whether full-length recombinant BLM has any effect on Fbw7-dependent c-Myc ubiquitylation. For these assays we used Fbw7, which led to a minimal level of c-Myc ubiquitylation, consequently allowing us to better visualize the effect of BLM. The amount of in vitro translated c-Myc used for the ubiquitylation reactions was the same in all experiments ( Fig. 5A , middle panel). BLM (1-1417) enhanced Fbw7-mediated c-Myc ubiquitylation in vitro, as detected by using antibody against c-Myc. The extent of enhancement was the same for Fbw7c and Fbw7a (Fig. 5A, top panel) . The blot was subsequently probed with antibody against FK2, which recognized both mono-and poly-ubiquitylated conjugates. BLM enhanced both mono-and poly-ubiquitylation of c-Myc (Fig. 5A , middle panel). A helicase-dead BLM (K695A) mutant also stimulated ubiquitylation to the same extent as wild-type BLM (Fig. 5B) , indicating that the stimulatory function of BLM on c-Myc ubiquitylation was not dependent on its DNA unwinding activity.
Next we wanted to determine the effect of BLM on Fbw7mediated c-Myc ubiquitylation in context of its known requirement for phosphorylation at Thr58 and Ser62 residues. Interestingly, the effect of BLM on c-Myc ubiquitylation was less for the c-Myc (T58A, S62A) mutant when compared with wildtype c-Myc (supplementary material Fig. S4C ). Moreover, BLM could not stimulate Fbw7c-dependent c-Myc ubiquitylation in presence of either GSK3b inhibitor ( Fig. 5C ) or l phosphatase (supplementary material Fig. S4D ). Together, these results provide evidence that the GSK3b-dependent phosphorylation of c-Myc at Ser58 and Thr62 residues is a prerequisite for BLM in order to enhance c-Myc ubiquitylation.
To show that BLM, indeed, regulates c-Myc ubiquitylation in vivo, reciprocal immunoprecipitations with either anti-K48linked ubiquitin (Fig. 5D ) or c-Myc (Fig. 5E ) were carried out. Although more endogenous c-Myc was present in the BS cells, K48-linked ubiquitylated forms of c-Myc were enhanced in A-15 cells (Fig. 5D,E) . Hence, depletion of Fbw7 in A-15 cells through corresponding small interfering RNA (siRNA) (validated by the stabilization of c-Myc) ( Fig. 5F, right) led to a huge decrease of c-Myc ubiquiylation in A-15 cells (Fig. 5F, left) , providing evidence that the presence of BLM enhanced Fbw7-mediated c-Myc degradation in vivo. 
BLM regulates the expression of c-Myc target genes
We hypothesized that, by enhancing Fbw7-mediated c-Myc ubiquitylation and subsequent degradation, BLM can also affect the mRNA expression profiles of the c-Myc target genes. At first, to determine the genes whose transcript expression profile depend on BLM, we carried out microarray hybridization on mRNA extracted from BS/A-15 cells. Altogether, 2332 genes were differentially expressed due to the lack of BLM in BS cells; a detailed analysis of which will be reported later. Next, we wanted to determine the c-Myc target genes that are deregulated in A-15 cells. However, it was not possible to obtain complete depletion of endogenous c-Myc in A-15 cells and, thereby, we were unable to carry out a subsequent microarray in A-15 cells (with or without c-Myc). Hence, for the next stage the 2332 BLM-dependent genes were compared with the non-redundant 1672 genes listed in the c-Myc target database (www.myccancer-gene.org/) (Zeller et al., 2003) , and whose expression was reported to be either activated or repressed by c-Myc. Comparison of the two gene lists indicated that 131 c-Myc target genes were differentially expressed in BS and A-15 cells (supplementary material Table S1). These genes (7.8% of all c-Myc target genes and 5.6% of all the genes differentially regulated owing to the absence of BLM) qualified to be the c-Myc targets whose expression was regulated by BLM. Out of the 131 genes, 64 genes were upregulated while 67 were downregulated to a variable extent in the absence of BLM (Fig. 6A,B ; supplementary material Table S1 ). Since only 131 out of 1672 c-Myc target genes were regulated by BLM, other factors possibly regulate the rest of the c-Myc target genes through parallel regulatory processes.
To validate the above analysis, mRNA expression pattern of c-Myc target genes differentially expressed in BS and A-15 cells were verified at the RNA level either by RT-PCR ( Fig. 6C ; supplementary material Table S2 ) or by real-time PCR (supplementary material Table S2 ). mRNA transcript patterns of the same set of genes were also checked in a second isogenic pair of cell lines (HCT116 BLM and HCT116 BLM 2/2 ) cells by RT-PCR (supplementary material Table S2 ). Gene expression patterns of 34 out of the 67 downregulated genes and 32 out of the 64 upregulated genes (66 out of the 131 genes i.e. 50.3% of the total subset) were analysed cumulatively by using RT-PCR and real-time PCR. By these analyses, 28 out of the 34 c-Myc target genes (82.3%) whose expression was reported to be downregulated by the expression of BLM were verified. Similarly, in 25 out of the 32 target genes (78.1%) expression was found to be upregulated by the absence of BLM (supplementary material Table S2 , yellow shaded genes). Hence, gene expression analysis through multiple procedures established that at least 53 out of the 131 c-Myc target genes (40.4%) were regulated by BLM. Since the analysis had been carried out for only 66 out of the original 131 genes, a further increase in the number of BLM-regulated c-Myc target genes is anticipated. Interestingly, expression patterns for 16 out of the analyzed 66 c-Myc target genes (ten genes which were downregulated and six genes which were upregulated, cumulatively 24.2% of the total genes analyzed) were reversed in absence of BLM (supplementary material Table S2 , red shaded genes). Validation of protein expression of a subset of these genes was carried out in A-15 and BS cells ( Fig. 6E ; supplementary material Table S2 ), and at both RNA and protein level by transiently decreasing the expression of BLM in A-15 cells while expressing its cognate siRNA (supplementary material Fig.  S4E,F) . Hence, by enhancing c-Myc degradation, BLM also regulates the expression of a subset of c-Myc target genes.
BLM inhibits c-Myc driven tumor initiation in a mouse xenograft model
On the basis of the above results, it is possible that c-Myc functions on proliferative pathways were altered by the presence or absence of BLM. To test our hypothesis we generated a set of isogenic stable cell lines with the genotypes BLM + c-Myc + , BLM + c-Myc 2 , BLM 2 c-Myc + and BLM 2 c-Myc 2 . We could not use the A-15 and BS cell lines for this purpose because these fibroblast derivatives do not have tumorigenic potential (our unpublished data). Hence, two new cell lines, HCT116 sh-Myc (Clone #9 and #7) and HCT116 BLM 2/2 sh-Myc (Clone #5 and #13), were generated by stably coexpressing the Tet repressor (pcDNA6TR) and small hairpin RNA (shRNA) against c-Myc (pTER c-myc) (van de Wetering et al., 2003) in HCT116 and HCT116 BLM 2/2 cells. These cells, which express tetracyclineregulated sh-Myc, showed complete shutdown of c-Myc expression following the addition of tetracycline (supplementary material Fig. S5A ). In a time course study, we found that 1 mg/ml of tetracycline was sufficient to shut down c-Myc expression for up to 24 hours (supplementary material Fig.  S5B ). Titration with different concentrations of tetracycline revealed that 0.5 mg/ml of the antibiotic led to an almost complete shutdown of c-Myc protein expression within 12 hours (supplementary material Fig. S5C ).
Since the ability of the cells to penetrate through a barrier of reconstituted basement membrane correlates with their invasive potential, we carried out in vitro matrigel invasion assays with HCT116 sh-Myc and HCT116 BLM 2/2 sh-Myc cells in (see Material and Methods) presence and absence of tetracycline. Both the partial and total absence of c-Myc (obtained by using two different concentrations of tetracycline) decreased the invasive potential of the cells by almost half (compare the normal BLM + c-Myc + genotype with BLM + c-Myc 2 conditions under which Myc is decreased to a different extent). This indicates that the percentage of invasive HCT116 cells is largely due to c-Myc expression ( Fig. 7A; supplementary material Fig.  S6 ). However, compared with the normal condition (BLM + c-Myc + genotype), absence of BLM in presence of c-Myc (i.e. BLM 2 c-Myc + genotype) statistically enhanced invasive capability of the cells ,1.6 times, indicating that BLM is a crucial component regulating the invasive potential of c-Myc (Fig. 7A) .
To conclusively link the increased invasive potential of cells that express c-Myc but lack BLM (Fig. 7A) to the action of BLM on Fbw7, in vitro matrigel invasion assays were carried out in parallel in HCT116 (wild type) or HCT116 Fbw7 2/2 cells, in which the expression of BLM was shut down by transfecting its cognate siRNA (Fig. 7B. top) . As expected, owing to their respective tumor suppressive functions, ablation of BLM or Fbw7 alone mildly enhanced the invasion potential of the cells (Fig. 7B, bottom) . However, lack of both Fbw7 and BLM, i.e. BLM 2 Fbw7 2 genotype, which should also indicate the BLM 2 c-Myc + genotype, statistically enhanced the invasive potential five-to sixfold (Fig. 7B, bottom) . The invasive potential of BLM 2 Fbw7 2 cells was higher compared with BLM 2 c-Myc + cells (compare their respective invasion percentages in Fig. 7A,B) . The effect of BLM on the stability of other SCF Fbw7c substrates, such as cyclin E and c-Jun, might also contribute during the invasion process.
Next, the above studies were extended to a xenograft model in nude mice. The generated stable cell lines were subcutaneously injected into nude mice. Feeding of tetracycline to 50% of the animals led to the generation of four different genotypes within the microenvironment of the injected cells. The absence of BLM staining in HCT116 BLM 2/2 derivatives and ablation of c-Myc staining after tetracycline treatment were confirmed in the respective tumor sections (supplementary material Fig. S7 ). In accordance with the role of BLM as a tumor suppressor, its absence alone mildly accelerated tumor initiation [compare BLM + c-Myc + (9.1 days) with BLM 2 c-Myc + (5.4 days)]. Lack of c-Myc delayed tumor initiation in presence of BLM [compare BLM + c-Myc + (9.1 days) with BLM + c-Myc 2 (16.6 days)] and in absence of BLM [compare BLM 2 c-Myc + (5.4 days) with BLM 2 c-Myc 2 (9.2 days)] (Fig. 7C) . The delayed initiation of tumor formation owing to BLM expression (,1.7 times) was statistically significant (P50.044). Significantly, the initiation of the tumor formation was most delayed when BLM expression occured in the absence of c-Myc [compare BLM + c-Myc 2 (16.6 days) with any other genotype], thereby indicating that -apart from its intrinsic function as a tumor suppressor -BLM can also act on c-Myc, enhance its degradation and, thereby, delay tumor initiation to the maximal extent.
The role of c-Myc in diverse functions led us to determine the levels of proliferation and apoptosis in the tumor sections derived from nude mice through Ki67 staining and TUNEL assay ( Fig. 7D; supplementary material Fig. S7 ). The net proliferative capacity of the tumors (measured as the ratio of proliferation versus apoptosis) was decreased by the loss of c-Myc (compare BLM + c-Myc + with BLM + c-Myc 2 ) and increased by the loss of BLM (compare BLM + c-Myc + with BLM 2 c-Myc + ). Since the rate of proliferation is lower in BLM + c-Myc 2 , the tumor initiates later in these cells within the mouse xenograft model compared with BLM + c-Myc + (Fig. 7C) . Loss of BLM together with the presence of c-Myc increased the net proliferative capacity of the tumors (compare BLM 2 c-Myc + with any other genotypes). Expression of CD31 (a marker that indicates the extent of angiogenesis) was also highest in tumor sections of mice with a BLM 2 c-Myc + genotype ( Fig. 7E ; supplementary material Fig. S7 ). Together, these results indicate that the negative regulation of c-Myc stability through BLM lead to a delay in tumor initiation in nude mice (supplementary material Fig. S8 ).
Discussion
Apart from predisposition to multiple forms of cancer in BS patients (German, 1997) , enhanced risk of colorectal cancer is also apparent in individuals who are heterozygous for the BLM Ash alleles (Gruber et al., 2002) . Enhanced tumor formation also occurs in mice that are heterozygous for Blm mutation (Goss et al., 2002) . These mutant mice develop twice the number of intestinal tumors when crossed with mice that carry a mutation in the Apc tumor suppressor. We now provide mechanistic evidence how BLM may control the early stage of colorectal tumorigenesis. Dissecting the role of BLM in relation to c-Myc during neoplastic transformation was carried out using coloncancer-derived HCT116 derivatives (Fig. 7) . Incidentally, Myc has been identified as a target of the Apc pathway (He et al., 1998) . c-Myc is overexpressed at the RNA and protein levels at both early and late stages of almost 70% of colorectal tumors (Finley et al., 1989; Sikora et al., 1987) , and in multiple colon carcinoma cell lines, including HCT116 (He et al., 1998) . On the basis of the known functions of c-Myc, it is not surprising that the decrease in c-Myc expression lowers the invasive capability of the cells, delays the tumor initiation and decreases the ratio of proliferation versus apoptosis (Fig. 7A,C,D, compare BLM + c-Myc + with BLM + c-Myc 2 in each case). What is more significant is that the loss of BLM increases the invasive potential of the c-Myc-expressing cells, advances the time for tumor initiation in the xenograft model, increases the ratio of proliferation versus apoptosis and increases the expression of the angiogenesis marker, CD31 (Fig. 7A,C,D, compare BLM + c-Myc + with BLM 2 c-Myc + in each case). In combination with the biochemical data and the evidence obtained using endogenous proteins (Figs 1-5) , the effect of BLM on c-Myc target genes ( Fig. 6 ; supplementary material S4E,F; Tables S1, S2), the results from the xenograft mice model (Fig. 7) led us to believe that the delay in tumor initiation is a reflection of the negative regulatory effect of BLM on c-Myc stability and, subsequently, on the subset of c-Myc target genes, whose expression is controlled by the helicase.
Oncogenes such as Ras frequently synergize with Myc during the transformation process (Pelengaris et al., 2002) . In the genetic model of colorectal tumorigenesis (Fearon and Vogelstein, 1990) , Ras mutations are thought to be the initiating event in a subset of colorectal tumors. Adenomas with Ras mutations are more likely to progress than adenomas without Ras mutations. HCT116 cells also contain an activating Ras mutation. Tumors from HCT116 cells that lack the mutant Ras allele have been shown to be nontumorigenic (Shirasawa et al., 1993) , indicating that Ras is the dominant tumorigenic factor in these cells. Oncogenic Ras in HCT116 carries out its function by upregulating c-Myc levels (Ihle et al., 2009 ) by affecting the mRNA and the protein stability (Lloyd et al., 1989; Sears et al., 1999) . Hence, we hypothesize that BLM -by deregulating c-Myc during tumor initiation -also indirectly affects functions of activated Ras during the initiation step of colorectal tumorigenesis.
A large body of literature exists that has detailed the role of BLM as a helicase (Bachrati and Hickson, 2008) . However, evidence has accumulated that conclusively demonstrated the role of BLM as a sensor of DNA lesion, acting in multiple steps of the DNA-damage-response pathway (Tikoo and Sengupta, 2010) . It is tempting to speculate that BLM, by acting as a sensor of DNA damage, can also help stalling continuous rounds of cell cycles by negatively regulating Myc expression levels and, thereby, maintaining the genomic stability. Enhancement of c-Myc degradation and, thereby, negative regulation of tumor initiation provides further evidence for the helicase-independent function of BLM. This function of BLM, together with its roles during the multiple steps of the DNA-damage-signaling cascade (Tikoo and Sengupta, 2010) , account for the function of BLM as a caretaker tumor suppressor.
It is known that Fbw7 binds to c-Myc after the latter is phosphorylated through GSK3b within the phospho-degron motif Cdc4 phospho-degron (CPD), thereby initiating the degradation of c-Myc . However, parallel mechanisms of c-Myc ubiquitylation and degradation also exist. Skp2, another E3 ligase, is known to mediate phosphorylation independent degradation of c-Myc as well as its transcriptional activation (Kim et al., 2003; von der Lehr et al., 2003) . We have provided evidence that the effect of BLM is specifically on Fbw7 and not Skp2 (Fig. 3D) . Furthermore, we have demonstrated that the BLM-mediated enhancement in the c-Myc-Fbw7 interaction is not dependent on a specific phosphorylation of c-Myc at Thr58 and Ser62 (supplementary material Fig. S3B,E) . However, phosphorylation within the CPD is an essential requirement for BLM to subsequently enhance c-Myc ubiquitylation and, thereby, causing its degradation ( Fig. 5C; supplementary material S4B-D) . These results indicate that the effect of BLM in enhancing c-Myc ubiquitylation through degradation acts in conjunction with its known principal mechanism of turnover. Apart from GSK3b, other kinases such as Pim1 and Pim2 are also known to be involved in the degradation of c-Myc (Zhang et al., 2008) . Indeed, Pim1 is one of the c-Myc target genes that is also regulated by BLM (supplementary material Tables S1 and S2), and is highly expressed in cells that express BLM at both the RNA and protein level (see Pim1 transcript and protein levels in Fig. 6C-E) . Overall, the enhancement of Fbw7, mediated c-Myc degradation through BLM falls under an expanding category of additional regulatory circuitry that mediates c-Myc turnover.
Owing to its expression profile in diverse forms of cancer, c-Myc and c-Myc-driven pathways remain very attractive targets for anti-cancer therapy (Soucek et al., 2008) . A variety of strategies have been suggested (Albihn et al., 2010) , some of which are in the pre-clinical stage. It is interesting to note that, despite being an attractive target, till now not a single c-Mycspecific therapy is presently approved for clinical trials (http:// clinicaltrials.gov/). A therapy, on the basis of a decreased half-life of c-Myc, that uses derivatives of BLM could be an attractive option. Oncogene-induced replicative stress has already been shown to be effective in killing c-Myc-driven tumors (Murga et al., 2011) . Efforts maybe directed to obtain BLM derivatives that can increase c-Myc ubiquitylation and, hence, enhance its degradation.
Materials and Methods
Recombinants and siRNA pGEX4T-1 BLM (1-1417) (Srivastava et al., 2009 ), pGEX4T-1 BLM (1-212), pcDNA3 Flag BLM (gift from Ian Hickson), EGFP-C1 BLM (gift from Nathan Ellis), pGEX4T-1 BLM (191-660), pGEX4T-1 BLM (621-1041), pGEX4T-1 BLM (1001-1417) (Tripathi et al., 2008) . pSG5-Jun (gift from Bohdan Wasylyk). pGEX4T-1 c-Myc (300-410) were obtained by cloning the respective PCR products into the EcoR1/XhoI sites of the vector. pGEX4T-1 c-Myc (D300-410) was generated by a two-step cloning process. In the first step pGEX4T-1 c-Myc (1-299) was generated by cloning the PCR fragment into the BamH1-EcoR1 site of pGEX4T-1. In the second step c-Myc (411-439) was inserted in frame with c-Myc (1-299) at EcoR1-XhoI sites to generate pGEX4T-1 c-Myc (D300-410). pMAL Myc (1-451) was obtained by cloning the PCR fragment into the EcoR1-HindIII sites of pMAL-p2X vector. 3pX-Flag-myc-CMV-24 Fbw7a, 3pX-Flagmyc-CMV-24 Fbw7b, 3pX-Flag-myc-CMV-24 Fbw7c, 3pX-Flag-myc-CMV-24 Fbw7c, 3pX-Flag-myc-CMV-24 Fbw7c DN (which contains only the common region of the three Fbw7 isoforms) and pFLAG-Fbw7c DF (gift from Markus Welcker and Bruce Clurman). pET28b-Fbw7c was obtained by cloning the PCR fragment into the EcoR1/NotI sites of pET28b vector. pcDNA6TR (Invitrogen). pTER-c-Myc (gift from Marc van de Wetering). siRNA for Fbw7 (On target plus Smart Pool) was purchased from Dharamacon. siRNA for BLM (custom synthesis against the sequence 59-AGCAGCGAUGUGAUUUGCA-39) was purchased from Dharamacon. ON-TARGET plus non-targeting siRNA #1 from Dharmacon (D-001810-01-05) was used as the control siRNA. All transfections were carried out using Lipofectamine 2000 (Invitrogen). All siRNA transfections were carried out for 54 hours.
Antibodies
Anti-BLM: ab476 (Abcam), A300-110A (Bethyl), A300-120A (Bethyl), HPA005689 (Sigma). Anti-c-Myc: 13-2500, Clone 9E10 (Invitrogen), #9402 (Cell Signaling), sc-764, N-262 (Santa Cruz Biotechnology), ab39688 (Abcam). Anti-phosphorylated c-Myc (Thr58/Ser62): sc-8000-R (Santa Cruz Biotechnology). Anti-WRN: NB100-140 (Novus Biologicals). Anti-RECQL4: K6312 (De et al., 2012) . Anti-Cyclin E: 551159 (BD Pharmingen). Anti-c-Jun: ab31419 (Abcam). Anti-B MyB: ab12296 (Abcam). Anti-KLF5: ab24331 (Abcam). Anti-Actin: sc-8432 (Santa Cruz Biotechnology). Anti-Flag: F1804 (Sigma). Anti-Flag antibody beads: A2220 (Sigma). Anti-Fbw7: ab74054 Clone 3a9/1 (Abcam). Anti-polyHistidine: H1029 (Sigma). Anti-mono and poly ubiquitylated conjugates (Clone FK2): PW8810 (Enzo Life Sciences). Anti-K48 polyubiquitin: Apu2.07 (gift from Vishva M. Dixit). Anti-NPM1: ab15440 (Abcam). Anti-RPL27: ab74731 (Abcam). Anti-MIF: ab7207 (Abcam). Anti-MITF: ab12039 (Abcam). Anti-EGFR: ab2430. Anti-PIM1: ab66767 (Abcam). Anti-p53R2: ab8105 (Abcam). Anti-CDH2: ab19348 (Abcam). Anti-hsp90: sc-7947 (Santa Cruz Biotechnology). Anti-GSK3b (phospho S9) antibody: ab9769 (Abcam). Anti-CD31: ab28364 (Abcam). Anti-Ki67: ab166667 (Abcam).
Cell culture conditions, treatments and assays
hTERT-immortalized Bloom Syndrome fibroblasts from a Bloom Syndrome patient GM03509 (referred as BS cells) and chromosome 15 mini-chromosomecorrected BS fibroblasts GM03509 (referred as A-15 cells) were maintained as described (Sengupta et al., 2003) . Fibroblasts from another BS patient GM08505 were immortalized and complemented either with GFP + BLM (referred as GM08505 + GFP-BLM cells) or with GFP alone (referred as GM08505 + GFP) (gift from Nathan Ellis) (Hu et al., 2001) . The colorectal carcinoma cell line HCT116 and its isogenic counterpart in which BLM has been deleted through homologous recombination are referred to as HCT116 BLM 2/2 (gift from Bert Vogelstein) (Rajagopalan et al., 2004) . HCT116 and HCT116 Fbw7 2/2 (gift from Jonathan Grim and Bruce Clurman) (Grim et al., 2008) . 73-26hTERT and 73-26hTERT-WRN (gift from Judith Campisi) (Yannone et al., 2001) . AG05139, AG03587, D8903644-K and B1865425K (De et al., 2012) . LLnL (25 mM, Sigma) or MG132 (25 mM, Calbiochem) treatments were carried out for the final 3 h of the incubation. Cycloheximide (1 mM, Sigma) was added for either 2 hours or 6 hours, in cells grown in presence of serum. For pulse-chase experiments, cells were treated with 700 mCi S 35 -methionine (Board of Radiation and Isotope Technology, India) in serum-free, methionine-free medium for 30 minutes. The cells were subsequently washed and were grown for the indicated times in normal medium. The concentrations and amounts used for different treatments were: GSK3b inhibitor VIII (Calbiochem): 25 mM, l phosphatase (New England Biolabs): 100 units. GSK3b inhibitor VIII and l phosphatase were incubated with c-Myc for 1 hour prior to the interaction or ubiquitylation at 30˚C or 37˚C, respectively. GSK3b activity was measured using an assay kit (CS0990, Sigma) with c-32 P-ATP according to the manufacturer's protocol.
In vitro ubiquitylation SCF Fbw7a and SCF Fbw7c were obtained by transfecting 3pX-Flag-myc-CMV-24 Fbw7a, 3pX-Flag-myc-CMV-24 Fbw7c or pFLAG-Fbw7 DF into 293T cells. The SCF Fbw7 E3 complexes or its non-functional Fbw7 DF mutant were purified from the cells by immunoprecipitation (IP) using anti-Flag antibody beads, eluted out using Flag peptide (Sigma), checked for purity, evaluated and used for ubiquitylation assays. For ubiquitylation assays, 1 ml of in vitro translated c-Myc (,30 ng of the protein) was incubated at 30˚C for 1 hour with 100 ng of Uba1 (Calbiochem), 200 ng of UbcH5a (Calbiochem) and 6 mg of purified ubiquitin (Boston Biochem) and 0.5-2 ml of the eluted E3 ligase (depending on its activity). The reaction was carried out in a final volume of 20 ml in a ubiquitylation buffer containing 4 mM HEPES-NaOH (pH 7.9), 6 mM potassium acetate, 0.2 mM DTT, 0.5 mM MgCl 2 , 0.05 mM EDTA, 1% glycerol and 0.15 mM ATP. Soluble GST-tagged BLM (wild type or its derivatives), GSK3b inhibitor or l phosphatase were included as indicated.
Northern analysis, reverse-transcriptase PCR, real-time PCR Total RNA was isolated by Trizol reagent (Invitrogen). Northern analysis was done using 20 mg of the total RNA using the entire c-Myc (1-439) open reading frame as the probe. For reverse-transcriptase (RT)-PCR the primers used are listed in supplementary material Table S3 . Taqman gene expression assays for Myc and Actb (b actin) were obtained from Applied Biosystems. Real-time PCR analysis for the c-Myc target genes that were also regulated by BLM was carried out using customized TaqMan array 96-well plates (Catalog number 4413256). All RT-PCR and real-time PCR analyses were done at least thrice (each time in duplicates) in ABI PRISM 7000 according to manufacturer's instructions (Invitrogen).
Transfections, immunofluorescence, microscope image acquisition
Transfection for immunofluorescence experiments was carried out on coverslips by using Lipofectamine 2000 (Invitrogen) according to manufacturer's protocol. Cytoplasmic and nuclear extracts from cells were made using NE-PER Nuclear and Cytoplasmic Extraction Reagent (Pierce). For preparation of whole-cell lysates, the cells were lysed in RIPA buffer. For immunofluorescence, the cells were washed and fixed with ice-cold methanol:acetone (1:1) for 5 minutes before immunostaining. For confocal microscopy, the slides were analyzed on a Zeiss 510 Meta system with 636/1.4 oil immersion objective. The laser lines used were Argon 458/477/488/514 nm (for EGFP), DPSS 561 nm (for Texas Red) and a Chameleon Ultra autotunable femtosecond laser with a tuning range of 690-1050 nm (for DAPI). LSM5 software was used for image acquisition. Quantification was carried out after visualization of 200 cells. Numbers indicate the percentage of cells that show colocalization of the two proteins.
Microarray hybridization
Total RNA obtained from BS and A-15 cells was used for microarray gene expression analysis. The Applied Biosystems human genome survey microarray version 2.0 chip containing 32,878 oligonucleotide probes (60-mer) representing 29,098 individual human genes and more than 1000 control probes was used for microarray profiling. Digoxigenin-UTP-labeled cRNA was generated and linearly amplified from 1 mg of total RNA from each sample by using an Applied Biosystems Chemiluminescent reverse-transcription in-vitro transcription (RT-IVT) labeling kit according to the manufacturer's protocol. Duplicate microarray hybridizations were carried out and the raw data values of intensities were normalized using trimmed mean scale. Chemiluminescence detection and image acquisition were performed according to the manufacturer's protocol (Applied Biosystems). Signals were quantified and corrected for background, and final images and feature data were processed by using Applied Biosystems 1700 Chemiluminescent Microarray Analyzer software version 1.1. Obtained were lists of genes that were differentially expressed in the absence of BLM (.twofold change at 95% confidence with signal-to-noise ratio $3).
Generation of inducible stable lines
Stable cell lines HCT116 sh-Myc and HCT116 BLM 2/2 sh-Myc were generated using the tetracycline repressor, pcDNA6TR (Invitrogen) and a short hairpin RNA against Myc cloned into pTER vector, pTER c-myc (van de Wetering et al., 2003) . The two plasmids were co-transfected into HCT116 BLM+/+ and HCT116 BLM 2/2 cell lines at the ratio 10 mg:1 mg (pcDNA6TR:pTER c-myc) using Lipofectamine 2000 (Invitrogen). After phenotypic expression the cells were grown for 4 days in selective medium containing 15 mg/ml of blasticidin (Invitrogen) and 450 mg/ml zeocin (Invitrogen) to obtain the respective clones.
Matrigel-invasion assays
Matrigel-invasion assays were carried out in 6-well BD Biocoat Matrigel Invasion Chambers (BD Biosciences) according to the manufacturer's protocol. Tetracycline-inducible cell lines were grown in serum-free medium (in absence or presence of tetracycline) for 12 hours before being used for the assay. Postinvasion, the membranes were removed and observed at 406 magnification after staining with 1% Toluidiene Blue (Fluka) in 1% borax (Sigma) for 2 minutes. The entire experiment was repeated in parallel with control inserts. Percentage invasion was determined by the relative ratio of the mean number of cells invading through the matrigel insert membrane versus the number of cells invading through the control-insert membrane. The invasion assays were also carried out in parallel using HCT116 and HCT116 Fbw7 2/2 cells after transfecting them with siRNA BLM or siRNA control. Post-transfection the cells were either lysed to be checked for western analysis or trypsinized for setting up the invasion assays. All experiments were set up at least in triplicates and repeated independently three times. The P-values were obtained by using two-tailed student's t-test, unpaired data with unequal variance. Values are mean 6 s.d.
Nude mice experiments 6610 6 cells in 100 ml medium were mixed with matrigel (1:1 ratio) and injected subcutaneously into 6-weeks old female nude mice. For the entire duration of the experiment 50% of the mice were made to drink 5% sucrose water, whereas the rest drank 0.5 mg/ml tetracycline in 5% sucrose water. Mice were observed every day for tumor initiation (i.e. detecting tumors of at least 2-3 mm 3 ). The tumors were manually measured with calipers and the size was estimated using the ellipsoid formula of height6width6length60.5 (mm 3 ). All work on nude mice has been carried out in accordance with and approval of the National Institute of Immunology Animal Ethics Committee.
